A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.

GODELAINE, Danièle;Carrasco Bertrand, Javier;Brasseur, Francis;Neyns, Bart;Van Pel, Aline;et.al.
(2007) Cancer Immunology, Immunotherapy : other biological response modifications — Vol. 56, n° 6, p. 753-759 (2007)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 358.28 KB
Request a copy

Details

Authors
  • GODELAINE, DanièleUCLouvain
    Author
  • Carrasco Bertrand, JavierUCLouvain
    Author
  • Brasseur, FrancisUCLouvain
    Author
  • Neyns, Bart
    Author
  • Boon-Falleur, ThierryUCLouvain
    Author
  • Van Pel, AlineUCLouvain
    Author
Show more
Abstract
A panel of cytolytic T lymphocyte (CTL) clones was isolated from metastases and blood samples of a melanoma patient vaccinated with MAGE-3.A1-pulsed autologous dendritic cells. We report here the identification of a new antigen encoded by the MAGE-C2 cancer-germline gene. This antigen is recognized by some of these CTL on HLA-B*4403. The sequence of the peptide is SESIKKKVL. It is processed in various melanoma cell lines expressing MAGE-C2 and HLA-B*4403. Because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific and could therefore be used for peptide-based antitumoral vaccination.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

GODELAINE, D., Carrasco Bertrand, J., Brasseur, F., Neyns, B., Thielemans, K., Boon-Falleur, T., & Van Pel, A. (2007). A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. Cancer Immunology, Immunotherapy : other biological response modifications, 56(6), 753-759. https://doi.org/10.1007/s00262-006-0244-5 (Original work published 2007)